New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
An FDA advisory panel has unanimously endorsed Moderna's first-of-its-kind mRNA-based seasonal influenza vaccine, mRNA-1010.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 6.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: Reuters · Yahoo Finance · statnews.com · Nature · Los Angeles Times · CIDRAP · ScienceAlert.
How this dossier is built: methodology · AI policy · corrections.
📍 How it ended
An FDA advisory panel unanimously voted in favor of the benefit-risk profile of Moderna's mRNA-1010 seasonal influenza vaccine. FDA staff indicated that data may support its use in older adults.
Epilogue added 49d ago, after coverage quieted.
Coverage (9)
- Moderna flu shot data may support use in older adults, US FDA staff says Reuters · 67d ago
- Moderna just got a signal investors can’t ignore Yahoo Finance · 67d ago
- FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy statnews.com · 67d ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 67d ago
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine Yahoo Finance · 67d ago
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology Los Angeles Times · 67d ago
- MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine Yahoo Finance · 67d ago
- Moderna’s mRNA flu vaccine gets thumbs up from federal vaccine panel CIDRAP · 67d ago
- New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel ScienceAlert · 67d ago
What happened
An FDA advisory committee voted unanimously in favor of the benefit-risk profile for Moderna's investigational seasonal influenza vaccine, mRNA-1010. The vaccine utilizes mRNA technology to expand the B cell response breadth in humans.
Coverage from Reuters, the Los Angeles Times, and Stat News emphasizes that the vaccine was previously subject to controversy. Reuters further notes that FDA staff indicated the vaccine's data may support use in older adults.
Market reactions are highlighted by Yahoo Finance, which reports that Moderna's stock experienced its best week in over four years following the panel's endorsement.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 64d ago.
Questions people are asking
What is the name of the vaccine?
The investigational seasonal influenza vaccine is designated as mRNA-1010.
How did the FDA advisory panel vote?
The panel voted unanimously in favor of the vaccine's benefit-risk profile.
What is unique about this flu vaccine?
It is a first-of-its-kind flu vaccine using mRNA technology.
Which specific population might benefit from the vaccine according to FDA staff?
FDA staff stated that data may support its use in older adults.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say
The U.S. Department of Health and Human Services (HHS) is planning to create two new deputy commissioner roles at the FDA.
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance for the first blood-based biomarker test for Alzheimer's disease, developed through a partnership between Roche and Eli Lilly.
Bad Food
A recent Cyclospora outbreak has sparked debate about food safety and political influence in the US.
There’s a new type of flu vaccine for older adults this year. Can you get it?
A new mRNA flu vaccine for older adults has been approved, but availability remains uncertain.
Philip Morris gets FDA nod for 11 new nicotine pouches
The FDA's approval of 11 new nicotine pouches by Philip Morris is stirring market anticipation and regulatory scrutiny.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A once‑abandoned Moderna stock jumped 177% after a cancer‑vaccine breakthrough, sparking a biotech rally while political and misinformation challenges loom.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.